TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-317US	
In Re Application of	SHARMA et al.					
Application No. Filing Date Examine			ər	Customer No.	Group Art Unit	Confirmation No.
10/539,130		Unknow	n	26815	Unknown	2716
Title: PURE LEV	OFLOXACIN HEMI		ROCESSES	FOR PREPARA	ATION THERE	OF
☐ The Director as describe ☐ Ch.☐ Cre☐ ☐ Ch.☐ Ch.☐ Ch.☐ Ch.☐ Payment by	the amount of or is hereby authorize	i. ee required. TO-2038 is attache	ched. edit Deposit	Account No. 5	50-0912	
Certification I certify that this account is bein Patent and Trad (Date)	ate of Transmission b document and authoriza g facsimile transmitted emark Office (Fa Signature Printed Name of Person Sig ate may only be used	y Facsimile* tion to charge deposit to the United States	I hereby of with the U as first "Commiss 22313-145	certificate of Mail certify that this connited States Posta class mail in ioner for Patents, ion [37 CFR 1.8(a)) ine 19, 2006 Chate Signature of Per Chris	ling by First Class respondence is being Service with suffician envelope ac P.O. Box 1450, Ale	ng deposited cient postage ddressed to exandria, VA
William D. Hare, Es Reg. No. 44,739 CUSTOMER NO. 2	Mignature Horosq.		Dated:	June 19, 2006		

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. RLL-317US		
In Re A	application Of	f: SHARMA et al.				
Appli	cation No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/	10/539,130 Unknown 26815 Unknown 2716					
Title:	PURE LEV	OFLOXACIN HEMI	HYDRATE AND PROCESSES	FOR PREPAR	ATION THEREC	OF
			Address to: Commissioner for Paten P.O. Box 1450 Alexandria, VA 22313-14			
			37 CFR 1.97(b)			
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
			37 CFR 1.97(c)			
2.	CFR 1.97(Final Action	(b), provided that the on under 37 CFR 1	etement submitted herewith is less information Disclosure Stater .113, a Notice of Allowance in the application, and is accomp	ment is filed be under 37 CFR	efore the mailing 1.311, or an A	date of a
	☐ the	statement specified i	n 37 CFR 1.97(e);			
OR						
	☐ the	fee set forth in 37 CF	FR 1.17(p).			

NFORMATION	DISCLOSURE	CITATION
------------	------------	----------

Docket No.: RLL-317US | Serial No.: 10/539,130

Applicants: SHARMA et al.

Filed: 6/15/2005 Group:

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1_	5,053,407	10/1/1991	Hayakawa <i>et al.</i>	514	230.2	
	A2	5,545,737	8/13/1996	Sato et al.	544	101	
							-
			FOREIGN	N PATENT DOCUMEN	TS		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 444 678	9/4/1991	EPO	C07D	498/06	
	B2	WO 03/045329	6/5/2003	PCT	A61K		
		OTHER DOCUME	NTS (Includ	ding Author, Title, Date,	, Pertinent P	ages, Etc.)	
	C1	Pseudopolymorp	hs", <i>Chemi</i>	dration on the Formation on the Formation of the Control of the Co	Bulletin, <u>43</u> (4):649-653 (1995)
,	C2	Araki et al. "Chemical structure and physicoschemical properties of (S)-(-)-0-fluoro-2.3-					

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.